Stockwatch: The Salix lessons
This article was originally published in Scrip
Executive Summary
As Salix Pharmaceuticals becomes the latest in a long line of recent specialty pharmaceutical acquisitions by generic pharmaceutical companies, there are a few lessons from this transaction that any investor would do well to learn.